AC-262536

ID: ac262536

Aliases: AC-262, Accadrine

Type: compound

Route/form: oral preclinical SARM context

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• partial AR agonist

Optimization domains

• SARM
• body composition
• bone
• doping

Research basis

• Preclinical pharmacology supports AC-262536 as a selective AR ligand with partial agonist behavior.
• It is useful for mapping newer research-chemical SARMs that are mostly discussed without human data.
• The entry should be read as molecule identity and receptor pharmacology, not a proven mild cycle.

Limits, risks, and missing evidence

• No human efficacy package was identified in this pass.
• Forum claims should be treated as molecule-identity and dose-quality problems before performance claims.
• Partial agonism does not remove endocrine, lipid/liver, androgen-sensitive tissue, or doping concerns.

Risk flags

• research compound
• preclinical only
• sarm class risk
• product identity risk
• doping

Linked papers, labels, and reviews

1. Pharmacological characterization of AC-262536, a novel SARM
   preclinical / pubmed_ac262536_characterization_2008
   Functional and pharmacological characterization of AC-262536.
2. Selective androgen receptor modulators in preclinical and clinical development
   review / pubmed_sarms_preclinical_clinical_2009
   SARM class review covering multiple preclinical and early clinical programs.